Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioceres Crop Solutions (BIOX) Short-term Investments (2017 - 2025)

Bioceres Crop Solutions' Short-term Investments history spans 6 years, with the latest figure at $11.7 million for Q2 2024.

  • For Q2 2024, Short-term Investments fell 3.62% year-over-year to $11.7 million; the TTM value through Jun 2024 reached $11.7 million, down 3.62%, while the annual FY2024 figure was $11.7 million, 3.62% down from the prior year.
  • Short-term Investments for Q2 2024 was $11.7 million at Bioceres Crop Solutions, down from $12.1 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $12.1 million in Q2 2023 and bottomed at $425976.0 in Q2 2021.
  • The 5-year median for Short-term Investments is $7.8 million (2020), against an average of $7.5 million.
  • The largest annual shift saw Short-term Investments tumbled 94.52% in 2021 before it soared 1167.94% in 2022.
  • A 5-year view of Short-term Investments shows it stood at $7.8 million in 2020, then crashed by 94.52% to $425976.0 in 2021, then skyrocketed by 1167.94% to $5.4 million in 2022, then soared by 124.68% to $12.1 million in 2023, then fell by 3.62% to $11.7 million in 2024.
  • Per Business Quant, the three most recent readings for BIOX's Short-term Investments are $11.7 million (Q2 2024), $12.1 million (Q2 2023), and $5.4 million (Q2 2022).